Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...
For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug before it could work—forcing millions of patients to rely on daily injections.
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
Our Verdict: DirectMeds offers one of the most accessible NAD+ injection programs in the telehealth space. With LegitScript certification, 180,000+ customers, a 4.6-star Trustpilot rating, and ...
Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...
IV therapy delivers cancer medicine directly into a vein and often requires a longer infusion visit at a clinic or hospital. Subcutaneous therapy is an injection given under the skin and usually takes ...
Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
In this segment, Dr. Morrison discusses the clinical evidence supporting subcutaneous immunotherapy and explains the concept ...
The primary selling point of this subcutaneous formulation of pembrolizumab has been improved convenience and efficiency for patients and health care systems. It has been described as allowing ...
If you could inject yourself with a substance that purports to make you tanner, fitter and healthier, would you? Many people are saying “yes.” Online, social media influencers tout vials of substances ...